WO2000045771A3 - Suppression de la transformation de cellules par le facteur de transcription egr - Google Patents

Suppression de la transformation de cellules par le facteur de transcription egr Download PDF

Info

Publication number
WO2000045771A3
WO2000045771A3 PCT/US2000/002799 US0002799W WO0045771A3 WO 2000045771 A3 WO2000045771 A3 WO 2000045771A3 US 0002799 W US0002799 W US 0002799W WO 0045771 A3 WO0045771 A3 WO 0045771A3
Authority
WO
WIPO (PCT)
Prior art keywords
egr
expression
present
cell
tumor cell
Prior art date
Application number
PCT/US2000/002799
Other languages
English (en)
Other versions
WO2000045771A2 (fr
WO2000045771A9 (fr
Inventor
Daniel Mercola
Eileen Adamson
Original Assignee
Daniel Mercola
Eileen Adamson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daniel Mercola, Eileen Adamson filed Critical Daniel Mercola
Priority to AU44487/00A priority Critical patent/AU4448700A/en
Publication of WO2000045771A2 publication Critical patent/WO2000045771A2/fr
Publication of WO2000045771A3 publication Critical patent/WO2000045771A3/fr
Publication of WO2000045771A9 publication Critical patent/WO2000045771A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Cette invention concerne un procédé permettant d'augmenter l'expression d'un facteur anti-métastatique dans une cellule tumorale ou de faire obstacle à la métastase d'une cellule tumorale, faisant intervenir l'administration à une cellule tumorale d'un vecteur comprenant une séquence d'acide nucléique codant pour l'EGR ou une séquence d'acide nucléique codant pour une partie active de l'EGR. La présente invention comprend également: un procédé d'identification de composés ou de compositions permettant d'augmenter l'expression de l'EGR dans une cellule; des procédés d'identification de composés ou de compositions permettant d'augmenter ou de limiter l'expression de l'EGR dans une cellule, l'expression d'au moins un facteur anti-métastatique, ou l'adhérence d'une cellule à un substrat comprenant les compositions pharmaceutiques identifiées grâce à ces procédés; des procédés permettant de faire obstacle à la prolifération d'une cellule tumorale par augmentation de l'expression d'un facteur métastatique.
PCT/US2000/002799 1999-02-05 2000-02-04 Suppression de la transformation de cellules par le facteur de transcription egr WO2000045771A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU44487/00A AU4448700A (en) 1999-02-05 2000-02-04 Suppression of transformation of cells by the transcription factor egr

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11891299P 1999-02-05 1999-02-05
US60/118,912 1999-02-05

Publications (3)

Publication Number Publication Date
WO2000045771A2 WO2000045771A2 (fr) 2000-08-10
WO2000045771A3 true WO2000045771A3 (fr) 2000-12-07
WO2000045771A9 WO2000045771A9 (fr) 2001-09-20

Family

ID=22381501

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/002799 WO2000045771A2 (fr) 1999-02-05 2000-02-04 Suppression de la transformation de cellules par le facteur de transcription egr

Country Status (2)

Country Link
AU (1) AU4448700A (fr)
WO (1) WO2000045771A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ367699A0 (en) * 1999-10-26 1999-11-18 Unisearch Limited Treatment of cancer
US20050058673A1 (en) 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
US7981415B2 (en) 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
US7771720B2 (en) 2007-09-07 2010-08-10 Cisthera, Inc. Humanized PAI-1 antibodies
CN110408691A (zh) * 2019-08-09 2019-11-05 福建医科大学孟超肝胆医院(福州市传染病医院) 与预测肝移植术后排斥反应相关的标志物egr-1及其应用
CN114588264B (zh) * 2022-02-25 2023-05-16 上海大学 敲低或抑制egr3的试剂在制备心肌缺血再灌注损伤药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837692A (en) * 1994-04-07 1998-11-17 Mercola; Dan Inhibition of the mitogenic activity of PDGF by mammalian EGr

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837692A (en) * 1994-04-07 1998-11-17 Mercola; Dan Inhibition of the mitogenic activity of PDGF by mammalian EGr

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HUANG ET. AL.: "Egr-1 negatively regulates human tumor cell growth via the DNA-binding domain", CANCER RES., vol. 55, 1 November 1995 (1995-11-01), pages 5054 - 5062, XP002929760 *
LIU ET. AL.: "The trascription factor EGR-1 suppresses transformation of human fibrosarcoma HT1080 cells by coordinated induction of transforming growth factor-beta1, fibronectin, and plaminogen activator inhibitor-1", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 7, 12 February 1999 (1999-02-12), pages 4400 - 4411, XP002929759 *
LIU ET. AL.: "Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta1", PROC. NATL. ACAD. SCI USA, vol. 93, no. 21, October 1996 (1996-10-01), pages 11831 - 11836, XP002929758 *

Also Published As

Publication number Publication date
WO2000045771A2 (fr) 2000-08-10
WO2000045771A9 (fr) 2001-09-20
AU4448700A (en) 2000-08-25

Similar Documents

Publication Publication Date Title
WO2006073839A3 (fr) Proteases antifongiques acides
WO2006081008A3 (fr) Acides nucleiques pour l'apoptose de cellules cancereuses
HK1050378A1 (en) Inhibiting gene expression with dsrna
WO2002000858A3 (fr) Procedes et compositions destines a une saccharification et a une fermentation simultanees
WO2004056981A3 (fr) Polypeptides possedant une activite cellobiohydrolase ii polynucleotides codant pour ces polypeptides
CA2492096A1 (fr) Derives de 1-h-pyrrolidin-2,4-dione spirocyclique cis-alcoxysubstituee utilises comme insecticides
WO1999039740A3 (fr) Sensibilisation de cellules a des composes utilisant un apport de gene et de compose induit par lipides
WO2002069896A3 (fr) Apoptose de cellules cancereuses humaines induite par chimiotherapie et augmentee par connexine afin d'inhiber la proliferation de cellules cancereuses
WO2004044160A3 (fr) Compositions d'arn a interference avec muc1 et procedes derives
WO2001029222A3 (fr) Polypeptides ayant une activite phospholipase b et acides nucleiques codant ces derniers
WO2003089598A3 (fr) Polypeptides a activite xyloglucanase, et acides nucleiques codant ceux-ci
WO2005062918A3 (fr) Methodes permettant de traiter l'asthme
WO2005033287A3 (fr) Methodes d'identification d'un produit genique a voie de synthese biologique
TW200621284A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
WO2006005032A3 (fr) Polypeptides ayant l'activite d'alpha-glucosidase et polynucleotides les codant
WO2004110369A3 (fr) Proteine de surface cellulaire associee a la leucemie lymphoide chronique humaine
DK1157100T3 (da) Oxaloacetathydrolase-defekte svampeværtsceller
WO2000045771A3 (fr) Suppression de la transformation de cellules par le facteur de transcription egr
MX2008004899A (es) Compuestos y métodos para partículas de condensado de ácido ribonucleico de péptido para terapéuticos de arn.
WO2002028894A1 (fr) Gene se rapportant a la tolerance aux medicaments et utilisation associee
WO2006014490A3 (fr) Polypeptides a activite alpha-glucosidase et polynucleotides les codant
WO2006053565A3 (fr) Polypeptides antimicrobiens et polynucleotides les codant
WO2007071578A3 (fr) Procede de fabrication enzymatique d'acide 5-norbornene-2-carboxylique
WO2003064592A3 (fr) Inhibiteurs de transporteurs auto-inducteurs
WO2000041509A3 (fr) Polypeptides possedant une activite de phosphatase acide et acides nucleiques codant pour ceux-ci

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA NZ US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA NZ US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: C2

Designated state(s): AU CA NZ US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1-58, DESCRIPTION, REPLACED BY NEW PAGES 1-47; PAGES 59-63, CLAIMS, REPLACED BY NEW PAGES 48-52; PAGES 1/11-11/11, DRAWINGS, REPLACED BY NEW PAGES 1/11-11/11, PAGES 1/6-6/6, SEQUENCE LISTING, REPLACED BY NEW PAGES 1/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase